deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03288324

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus

Sponsor: Children's Hospital Medical Center, Cincinnati

Conditions Cutaneous Lupus Systemic Lupus Erythematosus
Interventions Tofacitinib
Updated 18 times since 2017 Last updated: Feb 11, 2026 Started: Aug 23, 2017 Primary completion: Nov 1, 2022 Completion: Dec 1, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Cutaneous Lupus and Systemic Lupus Erythematosus and is currently completed. Children's Hospital Medical Center, Cincinnati leads this study, which shows 18 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Mar 2019 · 7 months · monthly snapshot~Mar 2019 – ~Aug 2019 · 5 months · monthly snapshot~Aug 2019 – ~Feb 2020 · 6 months · monthly snapshot~Feb 2020 – ~Aug 2020 · 6 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Sep 2022 · 8 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Sep 2023 · 8 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Mar 2026 · 18 months · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

18 versions recorded

  1. Mar 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Mar 2026 [monthly]

    Completed PHASE1/PHASE2

  3. Aug 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Aug 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Jan 2023 — Sep 2023 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  2. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Jan 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Feb 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Aug 2019 — Feb 2020 [monthly]

    Recruiting PHASE1_PHASE2

  10. Mar 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Aug 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  13. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Aug 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Hospital Medical Center, Cincinnati
  • Pfizer
Data source: Children's Hospital Medical Center, Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations